|
Utilisation patterns and costs of lipid-lowering drugs in Switzerland 2013-2019.
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) |
|
ID |
4637344 |
Author(s) |
Reinau, Daphne; Schur, Nadine; Twerenbold, Sibylle; Blozik, Eva; Früh, Mathias; Signorell, Andri; Schwenkglenks, Matthias; Meier, Christoph R |
Author(s) at UniBasel |
Meier, Christoph R. Schwenkglenks, Matthias
|
Year |
2021 |
Title |
Utilisation patterns and costs of lipid-lowering drugs in Switzerland 2013-2019. |
Journal |
Swiss medical weekly |
Volume |
151 |
Pages / Article-Number |
w30018 |
Mesh terms |
Adult; Anticholesteremic Agents, economics, therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors, economics, therapeutic use; Hypolipidemic Agents, economics, therapeutic use; PCSK9 Inhibitors; Retrospective Studies; Switzerland |
Abstract |
To analyse utilisation patterns of lipid-lowering drugs and the related costs in Switzerland between the years 2013 and 2019.; We conducted a retrospective descriptive study using administrative claims data of persons aged ≥18 years enrolled with the health insurance company Helsana. To enable statements at the Swiss population level, results were extrapolated according to age, sex and canton of residence.; The overall prevalence of patients taking lipid-lowering drugs rose from 8.9% (n = 736,174) in 2013 to 11.6% (n = 841,682) in 2019, but varied markedly across regions, with highest values in Ticino and lowest values in Zurich. More than every third individual aged ≥65 years was treated with a lipid-lowering drug in 2019. Statins were by far the most commonly used drugs (>90% of prescriptions), followed by ezetimibe, fibrates and PCSK9 inhibitors. We observed a trend towards the prescription of more potent statins (atorvastatin, rosuvastatin) in recent years. Total costs of lipid-lowering drugs increased from CHF 222 million in 2013 to CHF 230 million in 2019 (+3.5%), whereas annual per capita costs decreased from CHF 302 in 2013 to CHF 273 in 2019 (-9.4%).; The increasing use of lipid-lowering drugs reflects current therapeutic guidelines, but results in high costs for the healthcare system. |
ISSN/ISBN |
1424-3997 |
Full Text on edoc |
|
Digital Object Identifier DOI |
10.4414/SMW.2021.w30018 |
PubMed ID |
http://www.ncbi.nlm.nih.gov/pubmed/34495601 |
|
|
|
MCSS v5.8 PRO. 0.344 sec, queries - 0.000 sec
©Universität Basel | Impressum
| |
01/05/2024
Research Database / FORSCHUNGSDATENBANK
|